Rosenberger Brian's Form 4 filing
Zynerba Pharmaceuticals, Inc. (ZYNE) · filed Jan 25, 2023
- Accession no.
- 0001062993-23-001385
- Filed
- Jan 25, 2023
- Trade date
- Jan 23-24, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $7.60K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rosenberger BrianCIK 0001695788 | Officer (VP, Commercial & Business Dev.) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2023 | Common Stock | SSaleDisposed | −12,663 | $0.60 | −$7,597.8 | 94,848 | Direct | |
| Jan 24, 2023 | Common Stock | AGrant or awardAcquired | +120,000 | $0.00 | $0 | 214,848 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.